

Literaturverzeichnis zum Titelthema „Augenheilkunde heute“

von Professor Dr. Christos Haritoglou, Bettina Deak, Professor Dr. Maximilian Schultheiß und Professor Dr. Thomas Klink
Bayerisches Ärzteblatt 4/2026, Seite 120 ff.

1. Mitchell P, Smith W, Chey T, Wang JJ, Chang A. Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia. *Ophthalmology*. 1997;104(6):1033-40.
2. Wise GN. Clinical features of idiopathic preretinal macular fibrosis. Schoenberg Lecture. *Am J Ophthalmol*. 1975;79(3):349-7.
3. Govetto A, Lalane RA, 3rd, Sarraf D, Figueroa MS, Hubschman JP. Insights Into Epiretinal Membranes: Presence of Ectopic Inner Foveal Layers and a New Optical Coherence Tomography Staging Scheme. *Am J Ophthalmol*. 2017;175:99-113.
4. Kunbaz A, Derin Sengun G, Sahin ZB, Mahjoub AHM, Beyzade Z, Ucdag F, et al. Visual and anatomical outcomes of epiretinal membrane surgery across milder vs. severe stages: a retrospective longitudinal study. *Int Ophthalmol*. 2026;46(1):98.
5. Park DW, Dugel PU, Garda J, Sipperley JO, Thach A, Sneed SR, et al. Macular pucker removal with and without internal limiting membrane peeling: pilot study. *Ophthalmology*. 2003;110(1):62-4.
6. Kim BH, Yoon CK, Bae K, Lee EK, Lee CH, Kim DI, et al. Influence of internal limiting membrane peeling during idiopathic epiretinal membrane removal: a randomized controlled trial. *Sci Rep*. 2025;15(1):17499.
7. Miller-Ellis E, Fleming GP. Then and Now: Medical Therapy for Glaucoma. *Ophthalmol Glaucoma*. 2025;8(5S):S33-S7.
8. Erb C, Konieczka K. [Rho kinase inhibitors as new local therapy option in primary open angle glaucoma]. *Ophthalmologie*. 2021;118(5):449-60.
9. Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. *PLoS One*. 2017;12(8):e0183142.
10. Dietlein TS, Hermann MM, Jordan JF. The medical and surgical treatment of glaucoma. *Dtsch Arztebl Int*. 2009;106(37):597-605; quiz 6.
11. Governatori L, Oliverio L, Mermoud A, Scampoli A, Sarati F, Carradori A, et al. PreserFlo MicroShunt versus trabeculectomy: an updated meta-analysis and systematic review. *Graefes Arch Clin Exp Ophthalmol*. 2025;263(4):885-99.
12. Hoffmann EM, Hengerer F, Klabe K, Schargus M, Thieme H, Voykov B. [Glaucoma surgery today]. *Ophthalmologie*. 2021;118(3):239-47.
13. Lim R. The surgical management of glaucoma: A review. *Clin Exp Ophthalmol*. 2022;50(2):213-31.
14. Pazos M, Traverso CE, Viswanathan A, European Glaucoma S, Guidelines Task F, Guidelines Writers A, et al. European Glaucoma Society - Terminology and guidelines for glaucoma, 6th Edition. *Br J Ophthalmol*. 2025;109(Suppl 1):1-212.
15. Casagrande M, Steinhorst NA, Dippel SK, Kück F, Grohmann C, Spitzer MS, et al. Central retinal artery occlusion - detection score. *Front Med (Lausanne)*. 2023;10:1129002.
16. Wenzel DA, Feltgen N, Steinhorst NA, Poli S, Spitzer MS, Schultheiss M. [Acute diagnostics of central retinal artery occlusion and biomarkers of ischemia : Diagnostics with consequences?]. *Ophthalmologie*. 2021;118(11):1099-106.
17. Hayreh SS, Zimmerman MB, Kimura A, Sanon A. Central retinal artery occlusion. *Retinal survival time*. *Exp Eye Res*. 2004;78(3):723-36.
18. Hayreh SS, Zimmerman MB. Central retinal artery occlusion: visual outcome. *Am J Ophthalmol*. 2005;140(3):376-91.

19. Schultheiss M, Hartig F, Spitzer MS, Feltgen N, Spitzer B, Husing J, et al. Intravenous thrombolysis in acute central retinal artery occlusion - A prospective interventional case series. *PLoS One*. 2018;13(5):e0198114.
20. Lavin P, Patrylo M, Hollar M, Espaillet KB, Kirshner H, Schrag M. Stroke Risk and Risk Factors in Patients With Central Retinal Artery Occlusion. *Am J Ophthalmol*. 2018;196:96-100.
21. Lee J, Kim SW, Lee SC, Kwon OW, Kim YD, Byeon SH. Co-occurrence of acute retinal artery occlusion and acute ischemic stroke: diffusion-weighted magnetic resonance imaging study. *Am J Ophthalmol*. 2014;157(6):1231-8.
22. Schrag M, Youn T, Schindler J, Kirshner H, Greer D. Intravenous Fibrinolytic Therapy in Central Retinal Artery Occlusion: A Patient-Level Meta-analysis. *JAMA Neurol*. 2015;72(10):1148-54.
23. Mac Grory B, Nackenoff A, Poli S, Spitzer MS, Nedelmann M, Guillon B, et al. Intravenous Fibrinolysis for Central Retinal Artery Occlusion: A Cohort Study and Updated Patient-Level Meta-Analysis. *Stroke*. 2020;51(7):2018-25.
24. Préterre C, Gaultier A, Obadia M, Vignal C, Mourand I, Plat J, et al. Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4-5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial. *Lancet Neurol*. 2025;24(11):909-19.
25. Ryan SJ, Jørstad Ø K, Skjelland M, Pesonen M, Simonsen CZ, Bek T, et al. A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion. *N Engl J Med*. 2026;394(5):442-50.
26. Poli S, Grohmann C, Wenzel DA, Poli K, Tünnerhoff J, Nedelmann M, et al. Early REperfusion therapy with intravenous alteplase for recovery of VISION in acute central retinal artery occlusion (REVISION): Study protocol of a phase III trial. *Int J Stroke*. 2024;19(7):823-9.